Back to Search
Start Over
Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer.
- Source :
- Medicina (1010660X); Jan2023, Vol. 59 Issue 1, p10, 12p
- Publication Year :
- 2023
-
Abstract
- Background and Objectives: Postoperative adjuvant therapy with uracil and tegafur (UFT) is often used for stage II colon cancer in Japan, but a limited number of studies have investigated the effects of UFT in these patients. Materials and Methods: We conducted a population-based cohort study in patients with resected stage II colon cancer comparing the outcomes after postoperative adjuvant chemotherapy with UFT with an observation-only group. The data were collected from the Taiwan National Health Insurance Research Database from 2000 to 2015. The outcomes of the study were disease-free survival (DFS) and overall survival (OS). The hazard ratios (HRs) were calculated using multivariate Cox proportional hazard regression models. Results: No differences in the DFS and OS were detected between the UFT (1137 patients) and observation (2779 patients) cohorts (DFS: adjusted HR 0.702; 95% confidence interval (CI) 0.489–1.024; p = 0.074) (OS: adjusted HR 0.894; 95% CI 0.542–1.186; p = 0.477). In the subgroup analyses of the different substages, UFT prolonged DFS in patients with stage IIA colon cancer (adjusted HR 0.652; 95% CI 0.352–0.951; p = 0.001) compared with DFS in the observation cohort, but no differences in the OS were detected (adjusted HR 0.734; 95% CI 0.475–1.093; p = 0.503). Conclusions: Our results show that DFS improved significantly in patients with stage IIA colon cancer receiving UFT as a postoperative adjuvant chemotherapy compared with DFS in the observation group. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 1010660X
- Volume :
- 59
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Medicina (1010660X)
- Publication Type :
- Academic Journal
- Accession number :
- 161476856
- Full Text :
- https://doi.org/10.3390/medicina59010010